Objective: Colon cancer is a leading global cancer-related cause of morbidity and mortality. The oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (FOLFOX) regimen is a standard chemotherapeutic approach used to treat colon cancer. However, chemoresistant tumor cells typically lead to the emergence of recurrent FOLFOX-resistant tumors after initial treatment. As such, it is vital that novel approaches to identifying and eliminating such chemoresistant tumors be developed in an effort to improve patient chemotherapy outcomes. Materials and Methods: In total, 100 samples of serum were obtained between April 2014 and April 2019 from patients who had been pathologically diagnosed with colon cancer from the Xiamen Haicang Hospital, and after these patients received FOLFOX chemotherapy treatment, serum samples were collected again. The expression of has_circ_0055625 in these serum samples was assessed via qPCR. Additionally, 5-FU IC50 values were detected via CCK-8 assay. Results: We found has_circ_0055625 to be significantly upregulated in colon cancer patient serum. After FOLFOX treatment, chemotherapy-resistance was associated with the upregulation of has_circ_0055625. Conclusion:In summary, these data may provide a foundation for future studies of chemotherapeutic resistance in patients undergoing FOLFOX treatment, potentially guiding treatment adjustment strategies. However, further work will be necessary to expand upon these findings.
associated with high response rates and decreased rates of neurotoxicity compared with higher dose WBRT. Our treatment policy for PCL patients with residual disease following chemotherapy is whole-brain irradiation to a total dose of 23.4 Gy in 13 fractions of 1.8 Gy followed by a sequential boost up to 45-50 Gy in 25 fractions of 1.8-2 Gy to the primary site/residual tumor. We propose a new methodology in order to limit the dose to the healthy brain to the prescribed dose by using composite planning (bias dose planning). Materials/Methods: We treated two patients with PCL and residual disease after chemotherapy using our methodology. First, we prepared a "standard plan", where the WBRT dose was planned first for volumetric arc therapy (VMAT) using the Monoco TPS (Elekta), followed by the sequential boost dose plan; second, a "bias plan" where the sequential boost dose was planned first, and only thereafter the WBRT dose using the bias dose planning option with the Monaco TPS in order to have a final composite plan corresponding to the prescribed doses. Results: Treatment plans resulting from bias dose planning had a markedly reduced dose to the brain outside of the boost. The mean dose to the brain minus the boost volume was of 25.00 Gy AE 0.5 Gy (Bias plan) vs 30.00 AE 0.6 Gy (standard plan). Conclusion: Composite planning of the boost first and only thereafter planning the dose to the brain taking the boost plan into account allows a reduction of 5 Gy to the healthy brain. To our knowledge, in lymphoma treatment, the total delivered dose is important, rather than the dose per fraction. We recommend this procedure for PCL radiations that have a sequential boost.
Background We used bioinformatic analysis and quantitative reverse transcription polymerase chain reaction (RT-qPCR) assays to investigate the association between plasma microRNAs (miRNAs) and stable warfarin dosage in a Chinese Han population. Methods Bioinformatics analysis was used to screen out potential warfarin dose-associated miRNAs. Three plasma miRNAs were validated in 99 samples by RT-qPCR. Kruskal–Wallis test and multivariate logistic regression were used to compare differences in plasma miRNAs expression levels between three warfarin dosage groups. Results There were significant between-group differences among the three dose groups for hsa-miR-133b expression (p = 0.005), but we observed an “n-shaped” dose-dependent curve rather than a linear relationship. Expression levels of hsa-miR-24-3p (p = 0.475) and hsa-miR-1276 (p = 0.558) were not significantly different in the multivariate logistic regression. Conclusion miRNAs have received extensive attention as ideal biomarkers and possible therapeutic targets for various diseases. However, they are not yet widely used in precision medicine. Our results indicate that hsa-miR-133b may be a possible reference factor for the warfarin dosage algorithm. These findings emphasize the importance of a comprehensive evaluation of complex relationships in warfarin dose prediction models and provide new avenues for future pharmacogenomics studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.